Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Change in Accured Expenses (2020 - 2025)

Tarsus Pharmaceuticals has reported Change in Accured Expenses over the past 6 years, most recently at $4.2 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $4.2 million for Q4 2025, down 6.0% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (down 24.13% YoY), and the annual figure for FY2025 was $2.0 million, down 24.13%.
  • Change in Accured Expenses for Q4 2025 was $4.2 million at Tarsus Pharmaceuticals, up from -$15.9 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for TARS hit a ceiling of $26.7 million in Q2 2024 and a floor of -$21.3 million in Q3 2024.
  • Median Change in Accured Expenses over the past 5 years was $55500.0 (2021), compared with a mean of $582500.0.
  • Biggest five-year swings in Change in Accured Expenses: surged 3168.48% in 2021 and later crashed 495.96% in 2024.
  • Tarsus Pharmaceuticals' Change in Accured Expenses stood at $552000.0 in 2021, then tumbled by 185.69% to -$473000.0 in 2022, then plummeted by 35.31% to -$640000.0 in 2023, then skyrocketed by 802.81% to $4.5 million in 2024, then dropped by 6.0% to $4.2 million in 2025.
  • The last three reported values for Change in Accured Expenses were $4.2 million (Q4 2025), -$15.9 million (Q3 2025), and $19.5 million (Q2 2025) per Business Quant data.